Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

ABACAVIR
Trade names: Trizivir (GSK); Ziagen (GSK)
Indications: HIV infections in combination with other
antiretrovirals
Category: Antiretroviral; Nucleoside analog reverse
transcriptase inhibitor
Half-life: 1.5 hours
Clinically important, potentially hazardous interactions
with: arbutamine, argatroban, arsenic
Reactions
Skin
Acute febrile neutrophilic dermatosis (Sweet’s syndrome)
(2004): Del Giudice P+, JAmAcadDermatol51(3), 474
Edema
(1999): Spruance SL, Skin and Allergy News October, 37
Erythroderma
(2001): Shapiro M+, The AIDS Reader 11, 222
Exanthems
(1999): Nathanson N (generalized) (from Internet) (observation)
(1999): Spruance SL, Skin and Allergy News October, 37
(1998): Saag M+, AIDS 12, F203
Pruritus
(1998): Saag M+, AIDS 12, F203
Rash (sic) (10–69%)
(2003): Lanzafame M+, Infez Med 11(1), 40
(2002): Kessler HA+, Clin Infect Dis 34(4), 535
(2001): Hetherington S+, Clin Ther 23(10), 1603
(2000): Hervey PS+, Drugs 60, 447 (5%)
(1999): Hughes W+, Antimicrob Agents Chemother 43, 609 (9%)
(1999): Spruance SL, Skin and Allergy News October, 37 (69%)
(1998): Foster RH+, Drugs 55, 729
(1998): Kessler H+, 36th Meeting of the Infectious Disease
Society of America, Denver Abstract 453 (10–15%)
(1998): Saag M+, AIDS 12, F203 (10–15%)
(1998): Staszewski S+, AIDS 12, F197 (10–15%)
Stevens–Johnson syndrome
(2002): Bossi P+, Clin Infect Dis 35(7), 902
Mucosal
Mucocutaneous lymph node syndrome (Kawasaki
syndrome)
(2002): Toerner JG+, Clin Infect Dis 34(1), 131
Oral ulceration
(1999): Spruance SL, Skin and Allergy News October, 37
Oral vesiculation
(2002): Fantry LE+, AIDS Patient Care STDS 16(1), 5
Other
Anaphylactoid reactions/Anaphylaxis (3%)
(2001): Frissen PH+, AIDS 15, 289
(1999): Spruance SL, Skin and Allergy News October, 37 (3–4%)
(1999): Walensky RP+, AIDS 13, 999
Chills
(1999): Escaut L+, AIDS 13, 1419
Cough
(2002): Peyriere H+, Allerg Immunol (Paris) 34(10), 359
(2001): Hetherington S+, Clin Ther 23(10), 1603 (10%)
Death
(2003): Peyriere H+, Ann Pharmacother 37(10), 1392 (1.8%)
Fever
(2003): Lanzafame M+, Infez Med 11(1), 40
Hypersensitivity (5%)
(2006): James JS, AIDS Treat News 419, 6
(2006): Moreno-Cuerda VJ+, Med Clin (Barc) 126(19), 744
ABACAVIR 1
(2006): Rauch A+, Clin Infect Dis 43(1), 99 (8%)
(2006): Stekler J+, AIDS 20(9), 1269
(2003): Easterbrook PJ+, HIV Med 4(4), 321
(2003): Lanzafame M+, Infez Med 11(1), 40
(2003): Peyriere H+, Ann Pharmacother 37(10), 1392 (8.5%)
(2002): AIDS Patient Care STDS 16(5), 242
(2002): Clay PG, Clin Ther 24(10), 1502
(2002): Dargere S+, AIDS 16(12), 1696
(2002): Flexner C, Hopkins HIV Rep 14(3), 5
(2002): Hetherington S+, Lancet 359(9312), 1121
(2002): Hewitt RG, Clin Infect Dis 34(8), 1137 (3.7%)
(2002): Kessler HA+, Clin Infect Dis 34(4), 535
(2002): Mallal S+, Lancet 359, 727 (5%)
(2002): Phillips EJ+, AIDS 16(16), 2223
(2002): Symonds W+, Clin Ther 24(4), 565
(2002): Toerner JG+, Clin Infect Dis 34(1), 131
(2001): Cutrell A+, International AIDS Society Conference on HIV
Buenos Aires Abstract 527
(2001): Frissen PH+, AIDS 15, 289
(2001): Hetherington S, AIDS Read 11(12), 620
(2001): Hetherington S+, Clin Ther 23(10), 1603 (4.3%)
(2001): Keiser P+, 8th Conferences on Retroviruses (Chicago)
Abstract 622
(2001): Loeliger AE+, AIDS 15(10), 1325
(2001): Peyriere H+, Ann Pharmacother 35(10), 1291
(2001): Shapiro M+, The AIDS Reader 11, 222
(2001): Wit FW+, AIDS 15(18), 2423
(2000): AIDS Read 10, 525
(2000): AIDS Treat News 337, 7
(2000): Prescrire Int 9, 67
(2000): Clay PG+, Ann Pharmacother 34, 247
(2000): GlaxoWellcome, Important Drug Warning July (severe or
fatal)
(2000): Hervey PS+, Drugs 60, 447 (3–5%)
(2000): Keiser P+, Conference on Retroviruses & Opportunistic
Infections (Chicago) Abstract 622
(1999): Escaut L+, AIDS 13, 1419
(1999): Miller JL, Am J Health Syst Pharm 56, 304
(1998): AIDS Patient Care SDS 12, 405
(1998): Newsline People AIDS Coalit N Y Feb, 35
(1998): Foster RH+, Drugs 55, 729 (2–3%)
(1998): Saag M+, AIDS 12, F203 (2–5%)
(1998): Staszewski S+, AIDS 12, F197
(1997): James JS, AIDS Treat News 285, 1, 5
Lipoatrophy
(2005): Nolan D+, Sex Health 2(3), 153
(2004): McComsey GA+, Clin Infect Dis 38(2), 263
Lipodystrophy
(2002): Bernasconi E+, J Acquir Immune Defic Syndr 31(1), 50
Myalgia/Myositis/Myopathy/Myotoxicity
(1999): Escaut L+, AIDS 13, 1419
(1999): Spruance SL, Skin and Allergy News October, 37
Nephrotoxicity
(2006): Ahmad M, JPostgradMed52(4), 296 (Fanconi syndrome)
Rhabdomyolysis
(2005): Fontaine C+, AIDS 19(16), 1927 (with ciprofibrate)